|
|
Build Your Online Product Catalogs?
| Product Name: |
High Purity Small-Molecule Inhibitor API CH5424802
|
| Supply Ability: |
100g |
| Related proudcts |
api, pharmaceutical, intermediate, |
| Specifications |
medicine grade |
| Price Term: |
FOB,CNF,CIF |
| Port of loading: |
Shenzhen |
| Minimum Order |
100 |
| Unit Price: |
2.5 |
|
High Purity Small-Molecule Inhibitor API CH5424802
(CAS: 1256580-46-7)
Chemical Information
Quick ***ails:
Product Name CH5424802
Other Name 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile;CH5424802;AF-802;CH-5424802/RG-7853;Alectinib (CH5424802);Alectinib;AF-802,RG-7853;9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile Alectinib (CH5424802)
Molecular Formula C30H34N4O2
Molecular Weight 482.62
Storage 3years in -20ºC
Targets ALK (F1174L) ALK ALK (R1275Q) INSR KDR
IC50 1 nM 1.9 nM 3.5 nM
IC50 550 nM 1.4 μM
Appearance White to Off-White Solid
Product Specifications
Pharmaceutical Grade
MOQ
100 grams
Payment
L/C, T/T, Western Union
Shipment
EMS, DHL, FedEx
Origion Hubei,China
Packing
Aluminium Foil Bag or as Required
Export Ability
Global
Product Description:
CH5424802 is a potent and selective ALK inhibitor. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers.
CH5424802 is a potent and selective ALK inhibitor with IC50 of 1.9 nM.Alterations in the anaplastic lymphoma kinase (ALK) gene have been implicated in human cancers. Among these findings, the fusion gene comprising EML4 and ALK has been identified in non-small cell lung cancer (NSCLC) and fusion of ALK to NPM1 has been observed in anaplastic large cell lymphoma (ALCL). The possibility of targeting ALK in human cancer was advanced with the launch of crizotinib for NSCLC in the U.S. in 2011. The development of resistance to crizotinib in tumors, however, has led to the need for second-generation ALK inhibitors. One of these, alectinib hydrochloride, has been found to be an orally active, potent and highly selective ALK inhibitor with activity in ALK-driven tumor models. Alectinib has shown preclinical activity against cancers with ALK gene alterations, including NSCLC cells exp |
| Company: |
Wuhan Newbio Pharm-tech Co., Ltd.
|
| Contact: |
Mr. Jason Edwards |
| Address: |
858, East Lake, High-Tech Development Zone, Wuhan, Hubei, China |
| Postcode: |
430075 |
| Tel: |
+86-027-87002705 |
| Fax: |
86-27-87050469 |
| E-mail: |
|
|
|
|
Home
